A cobalt-containing acidic amino acid complex and its use for treating cancer
US-2024398829-A1 · Dec 5, 2024 · US
Methods of treating Parkinson's disease using viral vectors
US9492415B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9492415-B2 |
| Application number | US-201213647155-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 8, 2012 |
| Priority date | May 27, 1998 |
| Publication date | Nov 15, 2016 |
| Grant date | Nov 15, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods of delivering viral vectors, particularly recombinant adeno-associated virus (rAAV) virions, to the central nervous system (CNS) using convection enhanced delivery (CED) are provided. The rAAV virions include a nucleic acid sequence encoding a therapeutic polypeptide. The methods can be used for treating CNS disorders such as for treating Parkinson's Disease.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for delivering recombinant adeno-associated virus (rAAV) virions to the brain of a subject, comprising administering via convection-enhanced delivery (CED) said rAAV virions into the central nervous system (CNS) of the subject, wherein said rAAV virions comprise a nucleic acid sequence encoding a therapeutic polypeptide, and at least 1×10 9 rAAV virions are administered and distribution of said rAAV virions over an area greater than 5 mm 2 is achieved. 2. The method of claim 1 , wherein the administering is done with an osmotic pump. 3. The method of claim 1 , wherein the administering is done with an infusion pump. 4. The method of claim 1 , wherein the nucleic acid sequence encodes an aromatic-amino-acid decarboxylase (AADC). 5. The method of claim 1 wherein the subject is a human. 6. The method of claim 1 , wherein the rAAV virions are administered into the striatum. 7. A method for delivering recombinant adeno-associated virus (rAAV) virions to the brain of a subject having a central nervous system (CNS) disorder, comprising administering via convection-enhanced delivery (CED) said virions into the CNS of the subject, wherein said virions comprise a nucleic acid sequence encoding a therapeutic polypeptide, and at least 1×10 9 rAAV virions are administered and distribution of said rAAV virions over an area greater than 5 mm 2 is achieved. 8. The method of claim 7 wherein the CNS disorder is Parkinson's disease, the rAAV virions are administered into the striatum and wherein the nucleic acid sequence encodes AADC.
Assignees
Inventors
Classifications
Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors · CPC title
viral genome or elements thereof as genetic vector · CPC title
Preparations containing radioactive substances for use in therapy or testing in vivo · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9492415B2 cover?
- Methods of delivering viral vectors, particularly recombinant adeno-associated virus (rAAV) virions, to the central nervous system (CNS) using convection enhanced delivery (CED) are provided. The rAAV virions include a nucleic acid sequence encoding a therapeutic polypeptide. The methods can be used for treating CNS disorders such as for treating Parkinson's Disease.
- Who is the assignee on this patent?
- Genzyme Corp, Univ California
- What technology area does this patent fall under?
- Primary CPC classification A61K31/198. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).